To determine whether PCOS exhibits a profile of chronic inflammation or immune dysregulation when analyzed across a diverse patient population, highlighting the differences between these two conditions.
Key Findings:
PCOS patients showed significantly lower levels of circulating immune markers compared to controls (P < .05).
Growth factors and proinflammatory cytokines were reduced in PCOS patients, independent of race.
Only IL-18 and C-X-C motif chemokine ligand 16 showed significant differences between Black and White women.
Interpretation:
The study challenges the notion of PCOS as a disorder of chronic low-grade inflammation, suggesting that immune suppression and impaired angiogenic signaling may be involved, particularly in nonobese patients.
Limitations:
Small sample size limits generalizability and may affect the robustness of the findings.
Lack of metabolic metrics in the analysis.
Conclusion:
Further research with larger sample sizes and metabolic metrics is needed to confirm findings before clinical application.
